Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Jun 4;20(1):67.
doi: 10.1186/s10194-019-0994-z.

Letter to the editor: European headache federation guidelines on the use of monoclonal antibodies acting on the calcitonin gene-related peptide or its receptor for migraine prevention

Daniel D Mikol  1 , Josefin Snellman  2
Affiliations
Comment

Letter to the editor: European headache federation guidelines on the use of monoclonal antibodies acting on the calcitonin gene-related peptide or its receptor for migraine prevention

Daniel D Mikol et al. J Headache Pain. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Daniel D. Mikol is a full-time employee of Amgen Inc. Thousand Oaks, California. Josefin Snellman is a full-time employee of Novartis Pharma A.G. Basel, Switzerland.

Figures

Fig. 1
Fig. 1
Proposed amends for Table 14
Fig. 2
Fig. 2
Proposed amends for Table 20
See this image and copyright information in PMC

Comment on

References

    1. Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20:6. doi: 10.1186/s10194-018-0955-y. - DOI - PMC - PubMed
    1. Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026–1037. doi: 10.1177/0333102418759786. - DOI - PubMed
    1. Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, et al. A controlled trial of Erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123–2132. doi: 10.1056/NEJMoa1705848. - DOI - PubMed
    1. Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(4):382–390. doi: 10.1016/S1474-4422(16)00019-3. - DOI - PubMed